Lifevantage Corp (LFVN) Return on Investment ROI from the fourth quarter of 2026 to fourth quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Lifevantage Corp  (NASDAQ: LFVN)


Lifevantage's ROI from its fourth quarter of 2026 to the fourth quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Lifevantage's ROI in the fourth quarter of 2026?
Lifevantage Corp achieved a return on average invested assets (ROI) of 11.84 % in its fourth quarter of 2026, which is below Lifevantage's average return on investment, which stands at 20.35%.

ROI decreased relative to the period ending Mar 31 2026, due to the decline in net income.

Within the Healthcare sector 53 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the third quarter of 2026 from 574 to 589.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
IV. Quarter		 (Mar 31 2026)
III. Quarter		 (Dec 31 2025)
II. Quarter		 (Sep 30 2025)
I. Quarter		 (Jun 30 2025)
IV. Quarter
Y / Y Investment Change TTM 2.78 % 8.9 % 14.71 % 4.55 % 0.93 %
Y / Y Net Income Change TTM -48.27 % -37.14 % 38.36 % 223.67 % 651.34 %
Investment (TTM) in Millions 42 42 45 43 45
Return On Investment (TTM) 11.84 % 13.2 % 17.77 % 23.83 % 23.52 %
LFVN's Overall Ranking # 589 # 574 # 114 # 187 # 217
Seq. Investment Change TTM -1.64 % -1.49 % 3.97 % 2.02 % 4.22 %
Seq. Net Income Change TTM -11.82 % -26.82 % -22.44 % 3.36 % 7.15 %
Net Income (TTM) in Millions 5 6 8 10 10

LFVN Company Profile >> Back to LFVN Roi Comparisons >> See Annual LFVN Return On Investment



Return On Investment LFVN's Ranking
Within: No.
Industry # 18
Sector # 54
Overall # 589

Return On Investment Statistics
High Average Low
40.71 %
20.35 %
-1.87 %
(Dec 31 2019)   (Mar 31 2023)







Financial Statements
Lifevantage's IV. Quarter Investments $ 42 Millions LFVN's Balance sheet
Lifevantage's IV. Quarter Income $ 1 Millions Quarterly LFVN's Income Statement
LFVN's Income by Division See LFVN's Income by Division


LFVN Annual Return On Investment (Jun 30 2026)
2026		 (Jun 30 2025)
2025		 (Jun 30 2024)
2024		 (Jun 30 2023)
2023		 (Jun 30 2022)
2022
Total Investments in Millions 42 45 38 47 45
Y / Y Investment Growth -6.39 % 17.77 % -18.33 % 3.42 % -15.98 %
Net Income in Millions 5 10 3 3 3
Y / Y Net Income Growth -48.27 % 233.84 % 15.63 % -18.59 % -75.8 %
Annual Return On Investment 12.11 % 21.92 % 7.73 % 5.46 % 6.94 %


Annual Roi Comment
In the fiscal year 2026 ROI decreased relative to the previous year to 12.11 %, due to deterioration of net income.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
LFVN's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for LFVN's Competitors
Subscribers only: Roi for Lifevantage's Suppliers
Subscribers only: Return On Investment for LFVN's Customers

Other Ratios
LFVN's Roa LFVN's Inventory Turnover Ratio LFVN's Growth Rates LFVN's Dividend Statistics
LFVN's Profitability Ratios LFVN's Asset Turnover Ratio LFVN's Dividend Growth
LFVN's Roe LFVN's Valuation Ratios LFVN's Financial Strength Ratios LFVN's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI
Acadia Pharmaceuticals Inc   31.05 %
Caredx Inc   29.42 %
Adma Biologics Inc   28.94 %
Protalix Biotherapeutics inc   25.72 %
Pro dex Inc   24.29 %
Innoviva Inc   23.33 %
Electromed Inc   23.18 %
Zevra Therapeutics Inc   22.90 %
Iradimed Corporation  22.57 %
Alnylam Pharmaceuticals Inc   22.10 %
Eton Pharmaceuticals Inc   21.31 %
Dexcom Inc   20.98 %
Healthcare Services Group Inc   20.93 %
Arcutis Biotherapeutics Inc   20.77 %
Chemed Corporation  20.13 %
Resmed Inc   20.01 %
Halozyme Therapeutics Inc   19.99 %
Vertex Pharmaceuticals Inc  19.97 %
Agilent Technologies inc   19.84 %
Illumina Inc   19.61 %
Puma Biotechnology Inc   19.60 %
United Therapeutics Corporation  19.53 %
Zoetis Inc   19.44 %
Krystal Biotech Inc   19.16 %
Carlisle Companies Incorporated  18.88 %
Neurocrine Biosciences Inc   17.51 %
Intuitive Surgical Inc   17.11 %
Theravance Biopharma inc   17.10 %
Standard Biotools Inc   16.38 %
Inspire Medical Systems inc   16.34 %

Date modified: 2026-09-12T06:11:30+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.